Chest
Original Research: INTERSTITIAL LUNG DISEASEPrevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Section snippets
Subjects
We retrospectively reviewed all patients with IPF who were seen at our clinic between June 1998 and December 2004. Our clinic serves as both an IPF and lung transplant referral center. We included patients who had undergone right-sided cardiac catheterization as part of their initial evaluation prior to being listed for lung transplantation. Spirometry obtained within 1 month of the catheterization was required for inclusion in the study. When available, we included data from the 6MWT performed
Results
During the study period, 79 patients with IPF who were evaluated in our clinic were referred for lung transplant evaluation and underwent right-heart catheterization. These individuals comprised the final cohort included in this analysis. No subjects were lost to follow-up, and none were excluded. The mean mPAP was 23.4 ± 5.1 mm Hg (range, 8 to 46 mm Hg) among the cohort (Fig 1). The criteria for PAH were present in 25 subjects (31.6%), with a mean mPAP of 29.5 ± 3.3 mm Hg, compared with 19.1 ±
Discussion
We have reported on the prevalence of PAH and its impact on survival among a large cohort of patients with advanced IPF, all of whom had pulmonary artery (PA) pressure measurements determined by right heart catheterization. Although it has been previously reported that PAH affects the prognosis of patients with IPF, most of the prior studies12, 13, 30, 31 were smaller, did not report outcomes, relied on estimates of PA pressures, and/or included a broader mix of patients. In our cohort, PAH is
References (37)
- et al.
The left ventricle in systemic lupus erythematosus: initial observations and a five-year follow-up in a university medical center population
Am Heart J
(1993) - et al.
Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension
Chest
(2001) - et al.
Outcomes for patients with sarcoidosis awaiting lung transplantation
Chest
(2002) - et al.
Predicting mortality in patients with sarcoidosis awaiting lung transplantation
Chest
(2003) - et al.
Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment
Respir Med
(2004) - et al.
Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful for predicting outcome?
Chest
(1997) - et al.
Effects of diagnosis on survival benefit of lung transplantation for end-stage lung disease
Lancet
(1998) - et al.
Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia: does Pao2predict survival?
Chest
(2002) - et al.
Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis
Pneumologie
(2000) - et al.
Mortality in systemic sclerosis (scleroderma)
Q J Med
(1992)
Severe pulmonary hypertension in histiocytosis X
Am J Respir Crit Care Med
Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients
Br J Rheumatol
Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension
J Rheumatol
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension: Primary Pulmonary Hypertension Study Group
Circulation
Raised pulmonary artery pressures measured with doppler echocardiography in rheumatoid arthritis patients
Rheumatology (Oxford)
Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease
Am J Respir Crit Care Med
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model
Am J Respir Crit Care Med
Survival in patients with primary pulmonary hypertension: results from a national prospective registry
Ann Intern Med
Cited by (701)
Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD
2024, Journal of Heart and Lung TransplantationPulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management
2023, The Lancet Respiratory MedicinePulmonary vascular fibrosis in pulmonary hypertension – The role of the extracellular matrix as a therapeutic target
2023, Pharmacology and Therapeutics
The authors have no potential financial conflicts of interests to disclose.
The opinions expressed herein are not to be construed as official or as reflecting the policies of either the Department of the Army or the Department of Defense.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).